Treatment of follicular and mantle cell non-Hodgkin's lymphoma with anti-CD20 antibody Rituximab after high-dose chemotherapy with autologous CD34+enriched peripheral blood stem cell transplantation.

被引：0
|
作者：
Brugger, W
Hirsch, J
Repp, R
Schlimok, G
Grunebach, F
Vogel, W
Kopp, HG
Aulitzky, W
Ganser, A
Gramatzki, M
Fehnle, K
Kanz, L
机构：
[1] Ctr Med, Tubingen, Germany
[2] Univ Erlangen Nurnberg, D-8520 Erlangen, Germany
[3] Zentralklinikum, Augsburg, Germany
[4] Robert Bosch Krankenhaus, Stuttgart, Germany
[5] MHH, Hannover, Germany
[6] Algora, Clin Res Org, Munich, Germany
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2075
引用
收藏
页码：482A / 483A
页数：2
相关论文
共 50 条
  • [1] Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
    DE Tsai
    HCF Moore
    CL Hardy
    DL Porter
    EY Loh
    DJ Vaughn
    S Luger
    SJ Schuster
    EA Stadtmauer
    Bone Marrow Transplantation, 1999, 24 : 521 - 526
  • [2] Rituximab (anti-CD20 monoclonal antibody) therapy for progressive intermediate-grade non-Hodgkin's lymphoma after high-dose therapy and autologous peripheral stem cell transplantation
    Tsai, DE
    Moore, HCF
    Hardy, CL
    Porter, DL
    Loh, EY
    Vaughn, DJ
    Luger, S
    Schuster, SJ
    Stadtmauer, EA
    BONE MARROW TRANSPLANTATION, 1999, 24 (05) : 521 - 526
  • [3] Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation
    Kaya, H
    Keung, YK
    Case, D
    Cruz, JM
    Perry, JJ
    Radford, JE
    Hurd, DD
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (10) : 544 - 549
  • [4] R-DHAP - sequential high-dose chemotherapy with autologous stem cell support in combination with the anti-CD20 antibody Rituximab in relapsed aggressive non-Hodgkin lymphoma
    Sieniawski, M
    Staak, JO
    Scheuss, H
    Glossmann, JP
    Diehl, V
    Engert, A
    Josting, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S247 - S248
  • [5] High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma
    Provencio, Mariano
    Fayad, Luis E.
    MEDICINA CLINICA, 2008, 130 (02): : 60 - 65
  • [6] High-dose chemotherapy followed by autologous and allogeneic hematopoietic stem cell transplantation in patients with follicular non-Hodgkin's lymphoma in the rituximab era
    Garcia Escobar, Ignacio
    Cantos Sanchez de Ibargueen, Blanca
    Calvo de Juan, Virginia
    Maximiano Alonso, C.
    Mendez Garcia, Miriam
    Sanchez Ruiz, Antonio Carlos
    Provencio Pulla, Mariano
    TUMORI JOURNAL, 2015, 101 (01): : 2 - 7
  • [7] Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation:: A multicenter phase II study.
    Brugger, W
    Hirsch, J
    Repp, R
    Grünebach, F
    Schlimok, C
    Vogel, W
    Kopp, HG
    Manz, M
    Brossart, P
    Aulitzky, W
    Ganser, A
    Gramatzki, M
    Fehnle, K
    Kanz, L
    BLOOD, 2002, 100 (11) : 644A - 644A
  • [8] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [9] Application of monoclonal anti-CD20 antibody rituximab in the treatment. of non-Hodgkin's lymphoma
    Mihaljevic, Biljana
    Jankovic, Snezana
    Jakovic, Ljubomir
    Jovanovic, Maja Perunicic
    Andelic, Bosko
    Milosevic, Violeta
    Sretenovic, Aleksandra
    Virijevic, Marjana
    Petrovic, Milan
    VOJNOSANITETSKI PREGLED, 2008, 65 (03) : 229 - 233
  • [10] Clonal selection of CD20-negative non-Hodgkin's lymphoma cells after treatment with anti-CD20 antibody rituximab
    Schmitz, K
    Brugger, W
    Weiss, B
    Kaiserling, E
    Kanz, L
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 106 (02) : 571 - 572
12345